# Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

Study · id `cardio:ct-nct02664649` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02664649](<https://clinicaltrials.gov/study/NCT02664649>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02664649

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 1510 participants.

## Technical summary

Registry record NCT02664649. Randomized; no masking; primary purpose treatment. Start 2016-08-26 (actual); primary completion 2020-10-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1510 participants (planned count; ClinicalTrials.gov record NCT02664649, source copy `cardio:ctgov-nct02664649-2021-02-25`, retrieved 2026-10-26)
- Started: 2016-08-26 (actual) (ClinicalTrials.gov record NCT02664649, source copy `cardio:ctgov-nct02664649-2021-02-25`, retrieved 2026-10-26)
- Primary completion: 2020-10-15 (actual) (ClinicalTrials.gov record NCT02664649, source copy `cardio:ctgov-nct02664649-2021-02-25`, retrieved 2026-10-26)
- Completion: 2020-10-15 (actual) (ClinicalTrials.gov record NCT02664649, source copy `cardio:ctgov-nct02664649-2021-02-25`, retrieved 2026-10-26)
- Countries: France; Germany; Italy; Spain (ClinicalTrials.gov record NCT02664649, source copy `cardio:ctgov-nct02664649-2021-02-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02664649-2021-02-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
- Acronym: ATLANTIS
- Condition: Symptomatic Aortic Stenosis
- Condition: Eligible for Transcatheter Aortic Valve Replacement
- Intervention (Drug): Apixaban
- Intervention (Drug): Standard of care
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Action Research Group
- Collaborator class: OTHER
- Collaborator: Bristol-Meyers Squibb & Pfizer
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Action Research Group (`cardio:org-action-research-group`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial (`cardio:pubmed-35583186`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy (`cardio:pubmed-36137682`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3951a54c969008c45a1cd89aebfcd4b01940d928f301148ecfaced4cdbb41668
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
